LEADER 00000nim a22004935a 4500 
003    MWT 
005    20191125034858.0 
006    m     o  h         
007    sz zunnnnnuned 
007    cr nnannnuuuua 
008    150902s2014    xxunnn es      i  n eng d 
020    9781452699882 (sound recording : hoopla Audio Book) 
020    1452699887 (sound recording : hoopla Audio Book) 
029    https://d2snwnmzyr8jue.cloudfront.net/
       ttm_9781452699882_180.jpeg 
028 42 MWT11412342 
037    11412342|bMidwest Tape, LLC|nhttp://www.midwesttapes.com 
040    Midwest|erda 
082 04 338.4/76151|223 
099    eAudiobook hoopla 
099    eAudiobook hoopla 
100 1  Werth, Barry. 
245 14 The antidote :|binside the world of new pharma|h[Hoopla 
       electronic resource] /|cBarry Werth. 
250    Unabridged. 
264  1 [United States] :|bTantor Audio,|c2014. 
264  2 |bMade available through hoopla 
300    1 online resource (1 audio file (16hr., 27 min.)) :
       |bdigital. 
336    spoken word|bspw|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
344    digital|hdigital recording|2rda 
347    data file|2rda 
506    Digital content provided by hoopla. 
511 1  Read by Sean Pratt. 
520    In 1989, the charismatic Joshua Boger left Merck, then 
       America's most admired business, to found a drug company 
       that would challenge industry giants and transform health 
       care. Barry Werth described the company's tumultuous early
       days during the AIDS crisis in The Billion-Dollar Molecule,
       a celebrated classic of science and business journalism. 
       Now he returns to tell a riveting story of Vertex's bold 
       endurance and eventual success. The $325-billion-a-year 
       pharmaceutical business is America's toughest and one of 
       its most profitable. It is riskier and more rigorous at 
       just about every stage than any other business, from the 
       towering biological uncertainties inherent in its mission 
       to treat disease; to the 30-to-1 failure rate in bringing 
       out a successful medicine even after a molecule clears all
       the hurdles to get to human testing; to the multibillion-
       dollar cost of ramping up a successful product; to 
       operating in the world's most regulated industry, matched 
       only by nuclear power. Werth captures the full scope of 
       Vertex's twenty-five-year drive to deliver breakthrough 
       medicines. At a time when America struggles to maintain 
       its innovative edge, The Antidote is a powerful inside 
       look at one of the most intriguing and important business 
       stories of recent decades. 
538    Mode of access: World Wide Web. 
610 20 Vertex Pharmaceuticals Incorporated. 
650  0 Drugs|xMarketing. 
650  0 Pharmaceutical industry|zUnited States. 
650  0 Pharmaceutical industry|zUnited States|xHistory. 
650  0 Pharmaceutical technology|zUnited States. 
700 1  Pratt, Sean. 
710 2  hoopla digital. 
856 40 |uhttps://www.hoopladigital.com/title/
       11412342?utm_source=MARC|zInstantly available on hoopla. 
856 42 |zCover image|uhttps://d2snwnmzyr8jue.cloudfront.net/
       ttm_9781452699882_180.jpeg